Cancer
therapeutics and vaccines developer AV Therapeutics announced that on Dec. 27,
its common stock began trading on the OTC Market Group’s OTCQB Marketplace
under the symbol “AVTH.”
The
company has identified and patented Capridine, a chemo therapeutic drug that
has demonstrated specific activity against prostate and colon cancer in
preclinical models. Capridine is anticipated to be AV Therapeutics’ frontline
product – specifically in prostate cancer, for which limited chemotherapy
treatments currently exist. Counting funding from the National Institutes of
Health and the Department of Defense, more than $6 million has been invested in
the development of the drug.
AV
Therapeutics plans to enter Phase I trials for Capridine in the second quarter
of 2014. These trials will be led by the Prostate Consortium, which is
comprised of 16 leading academic medical centers in the United States.
AV
Therapeutics is focused on the business of developing cancer therapeutics and
immunotherapeutic vaccines that can be used alone or combined with prevalent
treatment modalities like chemotherapy and radiation to treat active disease
and prevent metastases and recurrence. The company’s immune-therapeutics is
based on the capability of certain proprietary reagents to re-educate or
reprogram an immune system to target micro-metastases that were previously
unidentified. AV Therapeutics plans to clinically develop both approaches for
metastatic and early-stage prostate cancer.
For
more information, visit the company’s website at www.avtherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
